STOCK TITAN

Plus Therapeutics Inc - PSTV STOCK NEWS

Welcome to our dedicated news page for Plus Therapeutics (Ticker: PSTV), a resource for investors and traders seeking the latest updates and insights on Plus Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Plus Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Plus Therapeutics's position in the market.

Rhea-AI Summary
Biocept signs non-exclusive licensing agreement for CNSide with Plus Therapeutics for clinical trial on targeted radiotherapeutic. Plus will pay Biocept $150,000 upfront fee in stock and $6,000 per CSF tumor cell enumeration analysis. Positive validation of CNSide's clinical utility and potential future agreements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
59.52%
Tags
none
-
Rhea-AI Summary
Plus Therapeutics expands supply agreement with Biocept for exclusive license to CNSide assay for patients receiving CNS radiotherapy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-53.54%
Tags
none
-
Rhea-AI Summary
Plus Therapeutics announces treatment of first patient in Phase 1/2a clinical trial for leptomeningeal metastases
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.5%
Tags
Rhea-AI Summary
Plus Therapeutics to present at H.C. Wainwright conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.5%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.8%
Tags
-
Rhea-AI Summary
Plus Therapeutics reports positive data from ReSPECT-LM clinical study, demonstrating median overall survival of 10 months for patients with leptomeningeal metastases. FDA approves continuation to Phase 1 Part B. No dose limiting toxicities observed. 5 out of 10 treated patients remain alive. CSF tumor cell counts decreased by up to 91%. Key opinion leader roundtable to discuss data at 8:00 a.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.89%
Tags
Rhea-AI Summary
Plus Therapeutics, Inc. (PSTV) will report second quarter 2023 financial results on August 14, 2023, after market close. The management team will host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update. A live webcast will be available at ir.plustherapeutics.com/events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.23%
Tags
-
Rhea-AI Summary
Plus Therapeutics, Inc. (PSTV) to Discuss Latest Data from ReSPECT-LM Clinical Trial in Webinar
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.15%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.51%
Tags
conferences
Rhea-AI Summary
Plus Therapeutics, Inc. (PSTV) announces the appointment of Pius Maliakal, M. Pharm., Ph.D., as Vice President of Clinical Operations. Dr. Maliakal will focus on advancing the Company’s lead clinical trials, ReSPECT-GBM and ReSPECT-LM, and further developing the broader pipeline. With over 20 years of experience, he brings valuable expertise in oncologic clinical development and trial operations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.37%
Tags
management
Plus Therapeutics Inc

Nasdaq:PSTV

PSTV Rankings

PSTV Stock Data

8.10M
4.21M
1.45%
3.27%
1.07%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Austin

About PSTV

plus therapeutics, inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and manufacture of treatments for cancer and other diseases. its lead product candidate is doceplus, a protein-stabilized pegylated liposomal formulation of docetaxel for the treatment of small cell lung cancer. the company is also involved in developing doxoplus, a generic pegylated liposomal encapsulated doxorubicin to treat breast and ovarian cancer, multiple myeloma, and kaposi's sarcoma. it has a license agreement with nanotx, corp. to develop and commercialize nanotx's glioblastoma treatment. the company was formerly known as cytori therapeutics, inc. and changed its name to plus therapeutics, inc. in july 2019. plus therapeutics, inc. was founded in 1996 and is headquartered in austin, texas.